Criteria | Structured Finance | ABS: Global Financial Future Flow Transaction Methodology And Assumptions Nov 11

  • ID: 2024367
  • November 2011
  • Region: Global
  • Standard & Poors
1 of 2

These criteria will apply to all new and existing DPRs and MV financial future flow securitizations issued by banks rated by Standard & Poor's. These criteria do not apply to corporate or public finance future flow securitizations. This criteria document replaces the portion of "Criteria: Structured Finance: ABS: The Three Building Blocks of an Emerging Markets Future Flow Transaction Rating," published Nov. 16, 2004, that refers to "Building Block No. 1: Business Line Risk Assessment," with respect to financial institutions. This building block was previously based on "Bank Survivability Criteria," published March 24, 2004, which is no longer current. These criteria also replace the portion of the three building block criteria that refers to Building Block No. 2: "Structured Assessment."...

Companies mentioned in this report are:

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.